We serve Chemical Name:3-Fluoro-4-methyl-2-pyridinecarboxylic acid CAS:1211587-40-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Fluoro-4-methyl-2-pyridinecarboxylic acid
CAS.NO:1211587-40-4
Synonyms:2-Pyridinecarboxylic acid, 3-fluoro-4-methyl-;MFCD18257375;3-Fluoro-4-methyl-2-pyridinecarboxylic acid;3-Fluoro-4-methylpicolinic acid
Molecular Formula:C7H6FNO2
Molecular Weight:155.126
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:282.7±35.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.536
PSA:
Exact Mass:155.038254
LogP:0.31
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Pyridinecarboxylic acid, 3-fluoro-4-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Fluoro-4-methylpicolinic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Fluoro-4-methyl-2-pyridinecarboxylic acid Use and application,2-Pyridinecarboxylic acid, 3-fluoro-4-methyl- technical grade,usp/ep/jp grade.
Related News: The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 3-Fluoro-4-methyl-2-pyridinecarboxylic acid manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 3-Fluoro-4-methyl-2-pyridinecarboxylic acid supplier The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study. 3-Fluoro-4-methyl-2-pyridinecarboxylic acid vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 3-Fluoro-4-methyl-2-pyridinecarboxylic acid factory The FDA approval allows Biogen to sell its product over several years – with forecasts for potential annual sales reaching as high $10 billion to $50 billion – until the company completes a required follow-up study.
